Congenital Heart Disease (CHD) Market Growth Trend Forecast with latest research study released by Delvens evaluating the market risk side analysis, highlighting opportunities, and leveraging strategic and tactical decision-making support. The report provides information on market trends and development, growth drivers, technologies, and the changing investment structure of the Global Congenital Heart Disease (CHD) market.
The Congenital Heart Disease (CHD) market size was estimated at USD 4.47 billion in 2023 and is projected to reach USD 8.11 billion in 2030 at a CAGR of 8.87% during the forecast period 2023-2030.
Get Free Sample Report: https://www.delvens.com/get-free-sample/congenital-heart-disease-chd-market
Congenital Heart Disease (CHD) is a term used to describe a range of structural defects in the heart that are present at birth. These defects can involve the walls, valves, arteries, or veins of the heart, causing problems with blood flow and affecting the heart’s ability to pump blood effectively.
The growth of the global Congenital Heart Disease (CHD) market is mainly driven by rising prevalence of congenital heart disease globally. Moreover, increased awareness, improved diagnostic techniques, increased awareness and better access to healthcare are expected to drive the market further.
Regional Analysis
North America to Dominate the Market
North America is estimated to account for the largest market share during the forecast period. This is due to the high prevalence of congenital heart disease and technological advancements in early diagnosis of the disease.
Moreover, the strong presence of the key players in the region is expected to drive the market during the forecast period.
Competitive Landscape
- Abbott Laboratories
- AstraZeneca Plc
- Becton Dickson Co.
- Bio-Rad Laboratories
- Boston Scientific Corp.
- Laboratory Corporation of America Holdings (LabCorp)
- Hoffmann-La Roche Ltd.
- Glaxosmithkline Plc
- Janssen Pharmaceuticals, Inc.
- Medtronic
- Viatris Inc.
- Novartis Ag
- Pfizer, Inc.
- Randox Laboratories Ltd. and More
For More Inquiry Contact us: https://www.delvens.com/Inquire-before-buying/congenital-heart-disease-chd-market
Recent Developments
In June 2023, Pfizer relaunched Eliquis, an anticoagulant used to prevent the gradual increase in the prevalence of stroke due to heart condition called atrial fibrillation which is a major concern being a common cause of death among adults.
In July 2023, Novartis announced that the US Food and Drug Administration (FDA) approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy.
The Congenital Heart Disease (CHD) Market is segmented into various segments such as type, diagnosis, treatment, route of administration, end users, distribution channel, and region:
Based on Type
- Heart Valve Defects
- Heart Wall Defects
- Blood Vessel Defects
- Others
Based on Diagnosis
- Electrocardiogram
- Chest X-ray
- Echocardiogram
- Transoesophageal Echocardiogram
- Pulse Oximetry
- Exercise Stress Test
- Cardiac CT Scan or MRI
- Cardiac Catheterization
- Others
Based on Treatment
- Medications
- Surgery
- Watchful Waiting
- Others
Based on Route of Administration
- Oral
- Parenteral
- Others
Based on End Users
- Hospitals
- Specialty Clinics
- Others
Based on Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Access Full Report: https://www.delvens.com/report/congenital-heart-disease-chd-market
In addition to the market data for the Congenital Heart Disease (CHD) Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements.
Frequently Asked Questions
What are the years considered to study Congenital Heart Disease (CHD) Market?
The Congenital Heart Disease (CHD) Market is studied from 2023-2030.
What is the compound annual growth rate (CAGR) of the Congenital Heart Disease (CHD) Market?
The Congenital Heart Disease (CHD) Market is growing at a CAGR of 8.87% during the forecast period.
Which region holds the largest market share in Congenital Heart Disease (CHD) Market?
North America holds the highest share in 2022 for Congenital Heart Disease (CHD) Market.
More Reports From Delvens:
Clinical Analysis Market size was estimated at USD 61.3 billion in 2023 and is projected to reach USD 98.43 billion in 2030 at a CAGR of 7% during the forecast period 2024-2030.
Microbiology Analysis Market size was estimated at USD 5.45 billion in 2023 and is projected to reach USD 10.07 billion in 2030 at a CAGR of 9.15% during the forecast period 2024-2030.
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT Telecom, Chemicals Materials, Semiconductor Electronics, Energy, Pharmaceutical, Consumer Goods Services, Food Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-3290-6466
+1 214-377-1144
